Balyasny Asset Management L.P. Trims Stock Position in Qiagen (NYSE:QGEN)

Balyasny Asset Management L.P. reduced its position in Qiagen (NYSE:QGEN - Free Report) by 64.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,334 shares of the company's stock after selling 129,080 shares during the quarter. Balyasny Asset Management L.P.'s holdings in Qiagen were worth $3,177,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of QGEN. Barclays PLC lifted its position in Qiagen by 170.6% during the third quarter. Barclays PLC now owns 1,849,004 shares of the company's stock valued at $84,259,000 after purchasing an additional 1,165,594 shares during the last quarter. Tidal Investments LLC bought a new stake in Qiagen during the third quarter valued at approximately $490,000. GAMMA Investing LLC lifted its position in Qiagen by 170.1% during the fourth quarter. GAMMA Investing LLC now owns 1,518 shares of the company's stock valued at $68,000 after purchasing an additional 956 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Qiagen by 34.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 16,409 shares of the company's stock valued at $731,000 after purchasing an additional 4,225 shares during the last quarter. Finally, Park Avenue Securities LLC lifted its position in Qiagen by 32.1% during the fourth quarter. Park Avenue Securities LLC now owns 8,908 shares of the company's stock valued at $397,000 after purchasing an additional 2,166 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors.

Qiagen Trading Up 1.0%

Shares of NYSE QGEN traded up $0.41 during mid-day trading on Friday, hitting $42.65. The stock had a trading volume of 740,713 shares, compared to its average volume of 1,145,145. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. Qiagen has a 1 year low of $37.63 and a 1 year high of $49.30. The business has a 50 day moving average price of $40.97 and a two-hundred day moving average price of $41.81. The firm has a market cap of $9.48 billion, a P/E ratio of 118.76, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The company had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. During the same period in the previous year, the firm earned $0.44 earnings per share. The firm's revenue for the quarter was up 5.2% on a year-over-year basis. On average, equities analysts anticipate that Qiagen will post 2.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

QGEN has been the subject of several research analyst reports. UBS Group dropped their target price on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. StockNews.com raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Robert W. Baird lifted their price target on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Finally, Baird R W downgraded shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 19th. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $48.42.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.